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Abstract
Background—Congenital heart defects (CHDs) occur in approximately 8 per 1000 live births. 
Improvements in detection and treatment have increased survival. Few national estimates of the 
healthcare costs for infants, children and adolescents with CHDs are available.
Methods—We estimated hospital costs for hospitalizations using pediatric (0–20 years) hospital 
discharge data from the 2009 Healthcare Cost and Utilization Project Kids’ Inpatient Database 
(KID) for hospitalizations with CHD diagnoses. Estimates were up-weighted to be nationally 
representative. Mean costs were compared by demographic factors and presence of critical CHDs 
(CCHDs).
Results—Up-weighting of the KID generated an estimated 4,461,615 pediatric hospitalizations 
nationwide, excluding normal newborn births. The 163,980 (3.7%) pediatric hospitalizations with 
CHDs accounted for approximately $5.6 billion in hospital costs, representing 15.1% of costs for 
all pediatric hospitalizations in 2009. Approximately 17% of CHD hospitalizations had a CCHD, 
but it varied by age: approximately 14% of hospitalizations of infants, 30% of hospitalizations of 
patients aged 1 to 10 years, and 25% of hospitalizations of patients aged 11 to 20 years. Mean 
costs of CHD hospitalizations were higher in infancy ($36,601) than at older ages and were higher 
for hospitalizations with a CCHD diagnosis ($52,899). Hospitalizations with CCHDs accounted 
for 26.7% of all costs for CHD hospitalizations, with hypoplastic left heart syndrome, coarctation 
of the aorta, and tetralogy of Fallot having the highest total costs.
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Conclusion—Hospitalizations for children with CHDs have disproportionately high hospital 
costs compared with other pediatric hospitalizations, and the 17% of hospitalizations with CCHD 
diagnoses accounted for 27% of CHD hospital costs.
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Introduction
Congenital heart defects (CHDs) are the most common birth defect and are estimated to 
affect almost 1% of infants born in the United States (Reller et al., 2008). Approximately 
25% of newborns with CHDs have critical CHDs (CCHDs) (Botto et al., 2001; Mahle et al., 
2009). CCHDs are a subset of CHDs that require surgical or trans-catheter intervention 
before one year of age and are amenable to detection using pulse oximetry screening (Mahle 
et al., 2009; Kemper et al., 2011). Improvements in CHD detection and treatment have 
increased life expectancy among infants and children (Williams et al., 2006; Marelli et al., 
2007; Oster et al., 2013a). Many individuals with CHD of all ages will require lifelong care 
for these conditions. However, little is known about the healthcare needs of children and 
adolescents with CHDs or the impact of this population on hospital resource use.
Health services research, including costs of care, has been identified as a public health 
priority (Oster et al., 2013b). Rising health care costs underscore the need to provide 
efficient and effective care. A better understanding of the overall costs of care for CHDs and 
CCHDs in children and adolescents may help identify high cost surgical or medical 
healthcare needs in this population and identify the specific major contributors to overall 
CHD costs. (Oster et al., 2013b). Previous studies have identified CHDs having high cost 
hospitalizations. Hospitalizations among neonates discharged in 2003 with any of 35 
selected birth defects showed high hospital charges for several CHDs (hypoplastic left heart 
syndrome, truncus arteriosus, transposition of the great arteries, and coarctation of the aorta) 
compared with other birth defects (Centers for Disease Control and Prevention, 2007). 
Reports detailing CHD hospital resource use have generally focused on the first year of life 
and have found high hospital costs for this population (Connor et al., 2005; Centers for 
Disease Control and Prevention, 2007; Peterson et al., 2013). Few studies have evaluated 
hospital costs after 1 year of life or into childhood and adolescence (Connor et al., 2005; 
Russo and Elixhauser, 2007; Opotowsky et al., 2009; O’Leary et al., 2013). Specifically, 
current hospital resource use for individuals with CCHDs is not well known. To address 
these gaps we analyzed data from the 2009 Agency for Healthcare Research and Quality 
(AHRQ) Kids’ Inpatient Database (KID) (Agency for Healthcare Research and Quality, 
2011b) to estimate hospital costs of U.S. pediatric hospitalizations with CHD diagnoses. We 
quantified CHD hospital costs among children and adolescents and also examined costs by 
specific CCHD type.
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Materials and Methods
STUDY DESIGN AND DATA SOURCE
The KID is an all-payer inpatient administrative database maintained by AHRQ’s 
Healthcare Cost and Utilization Project (HCUP) (Agency for Healthcare Research and 
Quality, 2011b,c). The 2009 KID is a stratified random sample of all hospital discharges 
from almost all non-Federal short-term, community-based hospitals from 44 participating 
states within HCUP’s sampling frame (Agency for Health-care Research and Quality, 
2011c). The KID includes a 10% sample of all normal newborn discharges and an 80% 
sample of all other discharges of patients ≤20 years old from all sampling frame hospitals 
(Agency for Health-care Research and Quality, 2011c). KID data are provided at the 
hospital discharge level. Each observation represents one patient hospitalization; identifiable 
information is removed from the discharge summary by HCUP and hospitalizations cannot 
be linked to individual patients. Each discharge includes up to 25 International Classification 
of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) discharge diagnosis codes, 
demographic data, expected payer, hospital charges, and discharge disposition (routine, 
transferred, died in the hospital, etc.). Sample weights provided by HCUP allowed weighted 
data to be used to generate national estimates (Agency for Healthcare Research and Quality, 
2011c). This study used de-identified data; this analysis was determined not to be human 
subjects research and exempt from IRB review.
STUDY POPULATION AND CASE INCLUSION CRITERIA
We included hospital discharges occurring January 1 to December 31, 2009 of patients ≤20 
years of age with principal or secondary diagnosis codes indicating a CHD (ICD-9-CM 
codes 745.0–747.49). CHD hospitalizations were categorized as CCHD and noncritical 
CHD. CCHDs included 12 primary and secondary targets of universal screening for CHDs 
using pulse oximetry (Mahle et al., 2009; Kemper et al., 2011; Oster et al., 2013a). The 
primary targets (ICD-9-CM codes) were hypoplastic left heart syndrome (HLHS) (746.7), 
pulmonary atresia (746.01), tetralogy of Fallot (745.2), total anomalous pulmonary venous 
return (747.41), transposition of the great arteries (745.10), tricuspid atresia (746.1), and 
truncus arteriosus (745.0) (Mahle et al., 2009; Kemper et al., 2011). The secondary targets 
were double outlet right ventricle (745.11), single ventricle (745.3), Ebstein anomaly 
(746.2), coarctation or hypoplasia of aortic arch (747.10 [coarctation of the aorta]), and 
aortic interruption, atresia or hypoplasia (747.11, 747.22) (Mahle et al., 2009; Kemper et al., 
2011). All discharges with principal or secondary discharge diagnosis codes for CCHDs 
were considered to be CCHD discharges, regardless of other noncritical CHDs present and 
those costs were included in the CCHD category. Hospitalizations could have multiple CHD 
or CCHD diagnoses, but were only counted once for overall estimates of costs. For 
estimates of costs of individual CCHDs, hospitalizations were counted each time an 
individual CCHD ICD-9-CM code appeared and could be counted more than once.
STUDY VARIABLES
Hospital costs were the outcome of interest. Hospital charges represent what hospitals bill 
for services and do not include physician fees. HCUP provides hospital-specific and group-
average cost-to-charge ratios (CCRs) to convert hospital charges to costs. Group-average 
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CCRs denote a weighted average CCR estimate, banded by hospital state, urban/rural 
location, investor-owned/other-owned, and hospital bedsize (Agency for Healthcare 
Research and Quality, 2011a). Hospital costs were obtained by multiplying 2009 total 
hospital charges by hospital-specific 2009 CCRs. If hospital-specific CCRs were 
unavailable, group-average CCRs were used. For one state for which CCRs were not 
available for use, we used average regional hospital-specific CCRs, grouped by urban versus 
rural location and teaching status. Total costs were obtained by summing hospital costs for 
all hospitalizations. Mean costs were obtained by dividing the total cost by the total number 
of hospitalizations.
Hospitalizations missing age, but with an HCUP identifier denoting in-hospital birth, were 
set to zero years and included in the analysis as being <1 year old (Agency for Healthcare 
Research and Quality, 2011c). Age at admission was categorized into <1 year (birth 
hospitalizations and discharges occurring after the birth hospitalization but <1 year old), 1 to 
10 years old, and 11 to 20 years old. Age at admission was rounded down (i.e., a 10.5-year-
old would be in the 1- to 10-year-old category). Because multiple hospitalizations by the 
same patient cannot be tracked using HCUP data, it is possible that individuals with multiple 
hospitalizations may be counted in more than one age category if an individual had a 
birthday in between hospitalizations that placed him/her in a different age category (i.e., <1 
year to 1–10 years).
Expected payer was categorized based on the primary and secondary expected payers on the 
discharge summary: private (including HMOs), public (Medicare or Medicaid), other (self-
pay, no charge, or other), and mixed. By HCUP convention, patient race/ethnicity was 
categorized as non-Hispanic white, non-Hispanic black, Hispanic, or other. Discharge 
disposition was categorized as routine (i.e., to home), died in hospital, and other (transferred 
out, home health care, against medical advice, and alive, destination unknown). Presence of 
a major or minor operating room procedure was defined using HCUP procedure class tools 
(Agency for Healthcare Research and Quality, 2014). Hospitalizations with a valid operating 
room ICD-9-CM procedure code were categorized as having a major procedure; 
hospitalizations with a valid non-operating room ICD-9-CM procedure code were 
categorized as having a minor procedure; hospitalizations with no ICD-9-CM procedure 
codes were categorized as having no procedures. Hospitalizations were categorized 
according to the most invasive procedure code present (i.e., if a hospitalizations included a 
major and minor procedure code, it was counted once in the major procedure category). 
Preterm births were identified as <1 year olds with ICD-9-CM codes 765.0 to 765.28. Other 
noncardiac structural or chromosomal anomalies were defined as any ICD-9-CM code from 
740.0 to 757.9 and 759.0 to 759.9, excluding minor defects (Supplementary Appendix).
For all pediatric hospitalizations, we excluded discharges with missing age, missing hospital 
charges, and normal newborn births. CHD hospitalizations included those with principal or 
secondary codes for CHD diagnoses. If an infant hospitalization had a diagnosis of preterm 
birth and the only CHD diagnosis was patent ductus arteriosus (ICD-9-CM 747.0), then the 
hospitalization was excluded. Excluded hospitalizations were retained in the final dataset but 
not analyzed to ensure proper weighting and estimate correct standard errors (HCUP 
Technical Assistance, 2013).
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DATA ANALYSIS
We calculated the total number of pediatric hospitalizations, excluding normal newborns, 
the total number of pediatric hospitalizations with CHDs, and their costs in 2009. Cost 
estimates were right-skewed; we did not transform data because we wanted to compare 
arithmetic means (Diehr et al., 1999; McGhan et al., 2009). Mean costs per hospitalization 
were calculated for CHDs and stratified by variables of interest as well as age at 
hospitalization. Total and mean costs of hospitalizations with any CCHD were obtained and 
compared with costs of all hospitalizations with any noncritical CHD. Differences in means 
were evaluated with t tests or ANOVA tests; all p-values were two-sided. Supplemental 
analyses were conducted to examine factors associated with increased costs: (1) an ordinary 
least squares regression of the natural log of costs of all pediatric hospitalizations, 
controlling for CHDs; (2) an ordinary least squares regression of the natural log of costs 
among pediatric hospitalizations with CHDs; and (3) a quantile regression of the 10th, 25th, 
50th, 75th, and 90th percentiles of the natural log of costs. Because of the log 
transformations, results are presented as exp(β) and should be interpreted as percentage 
change. Quantile regression parameters estimate the change in the quantile of costs. All 
models adjusted for length of stay, age group, presence of a CCHD, gender, expected payer, 
race, median household income, discharge disposition, and presence of a procedure on the 
discharge record. The quantile regression was performed in SAS version 9.3 (SAS Institute, 
Cary, NC), but did not account for the complex sampling design of the KID. All other 
analyses were performed in SAS version 9.3 (SAS Institute) using SAS survey procedures to 
account for the KID’s complex sampling design.
Results
The 2009 KID included 3,407,146 pediatric discharges, sampled from 4121 hospitals. There 
were 1685 birth hospitalizations with missing ages in which age was set to zero years. 
Among all pediatric hospitalizations, 14,620 were missing age, 62,699 were missing hospital 
charges, and 249,158 were considered normal newborn births; these hospitalizations were 
excluded. The 3,080,669 observations remaining after applying our exclusion criteria 
represented a weighted nationwide estimate of 4,461,680 pediatric hospitalizations admitted 
for any reason (95% confidence interval [CI]: 4,275,622–4,647,738). Among remaining 
hospitalizations, we excluded 12,129 pediatric hospitalizations with a diagnosis of preterm 
birth with only a patent ductus arteriosus diagnosis and 2,955,225 pediatric hospitalizations 
whose discharge record did not include a CHD ICD-9-CM code and were presumed to be 
admitted for a non-CHD cause. After exclusions, there were 113,315 hospitalizations with a 
CHD diagnosis for analysis. Weighted, this represented 163,980 nationwide hospitalizations 
with CHDs (95% CI: 150,664–177,295), which accounted for 3.7% of pediatric 
hospitalizations. Of weighted CHD hospitalizations, 27,282 (95% CI: 22,558–32,007) had a 
principal diagnosis of a CHD and 136,697 (95% CI: 126,942–146,453) had a secondary 
diagnosis of a CHD. Among infants with a CHD, 33,839 (95% CI: 31,211–36,468) or 25.9% 
had a diagnosis of preterm birth. Among all hospitalizations with a CHD, 46,712 (95% CI: 
42,042–51,381) or 28.5% also had a diagnosis of another structural or chromosomal 
anomaly.
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In a supplemental ordinary least squares regression controlling for presence of CHD, length 
of stay, age, expected payer, sex, race, median income of patient zip code, discharge 
disposition, and presence of a major or minor operating procedure, pediatric hospitalizations 
with CHD still had significantly higher costs compared with pediatric patients without CHD 
(data not shown). Pediatric hospitalizations without a CHD diagnosis code had shorter 
lengths of stay per hospitalization compared with those with a CHD diagnosis code (4.3 
days [95% CI, 4.2–4.4] versus 14.4 days [95% CI, 13.9–14.9]) (p <0.001). Among the 
4,297,701 (95% CI, 4,122,735–4,472,667) pediatric hospitalizations without a CHD 
diagnosis code, 42.5% (1,827,898; 95% CI, 1,746,995–1,908,802) did not have a procedure 
recorded on their discharge record; 35.4% (1,520,374; 95% CI, 1,448,658–1,592,090) had a 
minor procedure recorded; and 22.1% (949,428; 95% CI, 907,285–991,571) had a major 
procedure recorded. Compared with those pediatric patients without a CHD diagnosis code, 
pediatric patients hospitalized with a CHD diagnosis code were more likely to have minor or 
major procedures recorded on their discharge record (p <0.001; Table 1). Among CHD 
hospitalizations in which the principal diagnosis was a CHD, the five principal procedures 
with the highest total costs (Million Dollars [M] [95% CI]) were: systemic to pulmonary 
artery shunt ($119.5 M [$90.9 M–$148.2 M]), total repair of tetralogy of Fallot ($90.9 M 
[$69.4 M–$112.4 M]), extracorporeal membrane oxygenation ($84.4 M [$56.7 M–$112.1 
M]), creation of a conduit between the atrium and pulmonary artery ($79.0 M [$61.7 M–
96.2 M]), and surgical occlusion of other thoracic vessels ($75.2 M [$58.6 M–$91.7 M]).
CHD COSTS
Total weighted costs for the 4.46 million pediatric hospitalizations (excluding 
uncomplicated newborn hospitalizations) were estimated to be $37,067,978,726 (mean =
$8308; 95% CI: $7932–$8684). Total weighted costs for the 163,980 CHD hospitalizations 
were $5,615,646,475 (mean =$34,246; 95% CI: $32,419–$36,073), representing 15.1% of 
total pediatric hospitalization costs. Costs were skewed to the right (a small number of 
hospitalizations had very high costs). Median costs of hospitalizations with a CHD diagnosis 
were $10,974 (25th–75th percentile: $2742–$36,714; 10th–90th percentile: $1311–$91,648). 
Excluding infants with a diagnosis of pre-term birth and CHD, total costs were estimated to 
be $3,384,290,957 (mean =$26,005; 95% CI: $23,874–$28,136); excluding hospitalizations 
that also included a diagnosis of another structural or chromosomal anomaly, total costs 
were estimated to be $3,363,832,004 (mean = $28,685; 95% CI: $26,988–$30,382); 
excluding hospitalizations with either preterm birth or another structural or chromosomal 
anomaly, total costs were estimated to be $1,885,688,446 (Mean =$20,350; 95% CI: 
$18,311–$22,405).
The majority of hospitalizations with CHDs occurred among patients <1 year old (n 
=130,512; 95% CI, 120,898–140,126), followed by hospitalizations of 1 to 10 years old (n 
=23,968; 95% CI, 20,510–27,425), and hospitalizations of 11 to 20 years old (n =9500; 95% 
CI, 8297–10,703) (Table 1). The majority of hospitalizations with CHDs among patients <1 
and 1 to 10 years old had an expected public payer (47.9% and 45.2%, respectively) 
whereas, among hospitalizations with CHDs aged 11 to 20 years, the majority had an 
expected private payer (Table 1). Overall, approximately 41% of all hospitalizations with a 
CHD had a minor procedure; however, by age group, the majority of hospitalizations among 
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patients aged 1 to 10 and 11 to 20 had a major procedure (47.9% and 46.6%, respectively) 
(Table 1).
Among all ages, CCHD hospitalizations had higher mean costs per hospitalization than did 
those with noncritical CHDs ($52,899 vs. $30,351, respectively). Patients that died while 
hospitalized had the highest mean costs per hospitalization (Table 2). Hospitalizations 
among patients <1 year old had the highest mean costs ($36,601) whereas, hospitalizations 
of 1- to 10-year-olds and 11- to 20-year-olds had similar mean costs ($25,498 and $24,961, 
respectively) (Table 2). The mean costs per hospitalization among those <1 year old whose 
discharge was routine ($30,595) were significantly higher compared with 1- to 10-year-olds 
($22,907) and 11- to 20-year-olds ($21,957) that were routinely discharged. Hospitalizations 
with a CCHD had significantly higher mean costs than hospitalizations without critical 
CHDs for patients <1 year old, 1 to 10 years old, and 11 to 20 years old. However, the 
difference between mean costs per hospitalization of CCHD and noncritical CHD 
hospitalizations decreased with increasing age (Table 2). At all ages, mean costs per 
hospitalization were significantly higher with the presence of a major procedure (Table 2).
Supplemental analyses assessed factors associated with increased hospital costs among 
pediatric hospitalizations with a CHD diagnosis code. In an adjusted linear regression, 
length of stay, presence of a CCHD, death while hospitalized, and presence of a minor or 
major procedure was significantly associated with increased hospital costs. However, 
younger ages were associated with significantly decreased costs (Supplementary Table S1, 
which is available online). Quantile regression analysis allowed a comparison of the impact 
of regression coefficients at different cost quantiles. Again, length of stay, presence of a 
CCHD, death while hospitalized, and presence of a minor or major procedure were strongly 
associated with increased costs (Supplementary Table S1). However, these factors were 
most strongly associated with increased costs in the 25th, 50th, and 75th percentiles 
(Supplementary Table S1).
CCHD COSTS
The 28,320 hospitalizations with a CCHD accounted for 17.3% of all CHD hospitalizations 
and 26.7% of hospital costs (Table 3). Among all ages, hospitalizations with total anomalous 
pulmonary venous return had the highest mean cost per hospitalization ($73,033), but 
hospitalizations with HLHS had the highest total cost ($333.1 M) (Table 3), representing 
5.9% of the total costs for pediatric CHD hospitalizations. The five most costly CCHD 
hospitalizations (by total cost in millions of dollars) were: HLHS ($333.1 M), coarctation of 
the aorta ($316.3 M), tetralogy of Fallot ($279.0 M), double outlet right ventricle ($202.9 
M), and transposition of the great arteries ($159.2 M). Among CCHD hospitalizations, those 
for Ebstein anomaly had the lowest mean costs ($42,565); mean costs per hospitalization for 
Ebstein anomaly remained significantly higher than mean costs per hospitalization for 
noncritical CHDs ($30,352, Table 2) (p <0.001). At all ages, hospitalizations with a CCHD 
diagnosis accounted for a disproportionately larger percentage of hospital costs than 
represented in the total number of hospitalizations with any CHD (Fig. 1). For example, 
hospitalizations among those aged <1 year old with HLHS represented 2.4% of all 
hospitalizations with CHD, but accounted for 5.4% of total hospital costs in that age group; 
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for hospitalizations 1 to 10 years old, HLHS hospitalizations represented 7.4% of all 
hospitalizations with CHD, but accounted for 11.3% of all costs in that age group (Fig. 1).
Discussion
Our analysis of 2009 KID data revealed that the costs for hospitalizations of pediatric 
patients (<20 years old) with CHDs surpassed $5.6 billion. Costs were highest for 
hospitalizations of patients less than one year of age, for hospitalizations of patients with a 
CCHD, or for hospitalizations in which the patient died in the hospital. However, high 
resource use was not limited to infancy; 14.6% of hospitalizations with CHD occurred in 1- 
to 10- year-olds and 5.8% occurred in children aged 11 to 20. The cost per hospitalization 
among 1- to 10- and 11- to 20-year-olds averaged roughly $25,000. Previous work has 
observed CHD hospitalizations of infants and neonates to be associated with high hospital 
charges (Centers for Disease Control and Prevention, 2007), as well as identified factors 
associated with high hospital costs, including increased surgical risk, complications during 
hospitalizations, late detection of a CCHD, and type of CCHD (Connor et al., 2005; 
Benavidez et al., 2007; Russo and Elixhauser, 2007; Peterson et al., 2013). Our results add 
to the literature by estimating the high costs of CHD hospitalizations and the specific CCHD 
contribution to costs after infancy, as well as identifying CCHDs associated with high 
hospital costs. Hospitalizations with CCHDs had disproportionately higher costs in 
comparison to total CHD hospitalizations. Among CCHDs, costs for those with HLHS 
surpassed $333 million, and accounted for 6% of the total cost of all hospitalizations with 
any CHD.
This study had several limitations. First, because the KID is an administrative database, we 
used ICD-9-CM codes to identify CHD hospitalizations, which are imperfect identifiers of 
CHDs (Frohnert et al., 2005; Strickland et al., 2008). Misclassification of patient 
hospitalizations with or without CHDs could bias estimates of cost in either direction. 
Additionally, we lacked patient-level data, preventing us from analyzing individual patient 
costs, re-admissions, hospital transfers, or the impact of individual patients with multiple 
CHD diagnoses on hospital costs. However, our goal was to examine total and mean 
hospital costs, as opposed to patient-level costs. Second, the accuracy of cost estimates is 
affected by variation of CCRs across and within each hospital (Rogowski, 1999). Hospital-
specific CCRs may not be appropriate for cost estimates of specialized procedures and 
diagnoses; however, as we did not have department-specific CCRs, these ratios were the 
best available. Third, in our analysis, cost estimates were right-skewed. A comparison of 
mean estimates can be problematic if some patients (e.g., because of complications or co-
morbidities) have higher costs (Diehr et al., 1999; McGhan et al., 2009). However, we chose 
to examine arithmetic means, which better characterize overall healthcare resource use than 
do medians (Diehr et al., 1999; McGhan et al., 2009). Fourth, our estimates of the costs of 
hospitalizations with CHD may be impacted by our exclusion criteria. We included CHD 
hospitalizations of preterm births, as well as CHD hospitalizations with noncardiac 
structural and chromosomal anomalies. These observations likely inflate the cost of 
hospitalizations with CHD beyond what should be expected for a CHD alone. In fact, 
removing those hospitalizations with either a preterm birth or additional congenital or 
chromosomal anomaly reduced total cost estimates by approximately 66%. However, we 
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sought to obtain an overall estimate of all CHD hospitalizations and excluding preterm 
births or other congenital anomalies would have excluded a large subset of those 
hospitalized with a CHD. Finally, while we provide race/ethnicity as coded in the KID, 
hospitals vary in how they report race/ethnicity. Moreover, race/ethnicity is likely not 
missing at random when not coded (Agency for Healthcare Research and Quality, 2011c). 
AHRQ generates disparity files restricted to 40% of HCUP discharges from states and 
hospitals with race/ethnicity data meeting specific criteria for accuracy (Coffey et al., 2010). 
While these patient exclusion criteria have been used in studies of healthcare disparities 
(Barocas et al., 2012), their application here would have precluded generating nationwide 
estimates.
CHDs are of public health importance due to their prevalence and severity. CCHDs are 
severe, require early interventions, and often require lifelong care and treatment (Warnes et 
al., 2001; Williams et al., 2006; Marelli et al., 2007; Oster et al., 2013a). Overall, 17.3% of 
all hospitalizations with a CHD had a CCHD; additionally, a greater percentage of 
hospitalizations with CCHD occurred for 1 to 10 and 11 to 20 year olds than for <1 year 
olds, indicating that these patients continue to receive inpatient care beyond infancy. Many 
individuals with CHDs surviving past infancy have CHDs of mid to high complexity and 
require lifelong care (Warnes et al., 2001; Williams et al., 2006). As the population of 
children and adolescents living with CHDs ages, the costs to hospitals for care incurred for 
individuals hospitalized for CHDs can be expected to increase. Research investigating 
factors associated with hospital costs for children and adolescents with CHDs and what 
types of inpatient hospital resources are consumed at these older ages is needed to plan for 
the future needs of this growing population.
Supplementary Material
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FIGURE 1. 
Total costs of hospitalizations with critical congenital heart defects as a percentage of total 
costs of all hospitalizations with any congenital heart defect; total hospitalizations with a 
critical congenital heart defect as a percentage of total hospitalizations with any congenital 
heart defect, by age. CHD, congenital heart defect; HLHS, hypo-plastic left heart syndrome; 
Coarc, coarctation of the aorta; ToF, tetralogy of Fallot; DORV, double outlet right 
ventricle; TGA, transposition of the great arteries; Single, single ventricle; Pulm Atr, 
pulmonary atresia; Aortic, interruption or hypoplasia of aortic arch; Tric Atr, tricuspid 
atresia; TAPVR, total anomalous pulmonary venous return; Truncus, truncus arteriosus; 
Ebstein, Ebstein anomaly
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